HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency

Yesterday, Hims & Hers Health, Inc. HIMS entered into a definitive agreement to acquire Boston-based YourBio Health, Inc. The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions.

YourBio’s, a renowned name in capillary whole blood sampling technology, TAP device, built on HALO technology, uses bladeless microneedles to produce high-quality capillary blood samples in seconds. This reduces the pain or complexity of traditional methods, like fingerstick or venipuncture.

The latest buyout is expected to significantly aid Hims & Hers in its efforts to enhance the overall blood collection experience through YourBio’s advanced blood sampling devices.

Trend in HIMS Stock Following the News

Following the announcement, shares of the company gained nearly 0.2% in overnight trading.

Historically, the company has gained a high level of synergies from its various deals. We expect market sentiment on the stock to remain positive around this announcement, too.

Hims & Hers currently has a market capitalization of $8.44 billion. It has an earnings yield of 1.3%, better than the industry’s negative yield. In the last reported quarter, HIMS delivered a negative earnings surprise of 33.3%.

Rationale Behind Hims & Hers’ Latest Acquisition

Per Hims & Hers, the acquisition is expected to enable it to bring into its portfolio the most advanced, pain-free blood sampling technology to date and proceed toward achieving user-centric blood sampling.

YourBio’s management believes its HALO and TAP technologies have the potential to change how people engage with routine blood collection — replacing long waits and painful needles with a far more convenient, user-friendly experience.

Industry Prospects in Favor of HIMS

Per a report by Grand View Research, the global capillary blood collection devices market was estimated at $2.13 billion in 2024 and is anticipated to reach $3.52 billion by 2030 at a CAGR of 8.8%. Factors like the rising availability of Point-of-Care diagnostics and the increasing prevalence of chronic diseases, such as diabetes, are likely to drive the market.

Given the market potential, the latest acquisition is expected to provide a significant boost to Hims & Hers’ business.

Hims & Hers’ Notable Deals

In July, Hims & Hers announced its plans to bring its affordable, holistic weight loss program to Canada. The company’s entry into Canada will likely come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care.

In June, Hims & Hers announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS’ footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon.

HIMS’ Share Price Performance

Shares of the company have gained 20.7% in the past year against the industry’s 0.5% decline. The S&P 500 has gained 15.6% in the same time frame.

Hims & Hers’ Zacks Rank & Key Picks

Currently, HIMS carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Solventum Corporation SOLV, Intuitive Surgical, Inc. ISRG and IDEXX Laboratories, Inc. IDXX.

Solventum, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 1.6%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Solventum’s shares have gained 22.1% compared with the industry’s 0.9% rise in the past year.

Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.3%.

Intuitive Surgical has rallied 4.1% compared with the industry’s 0.4% gain in the past year.

IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.

IDEXX’s shares have gained 68.4% compared with the industry’s 0.4% gain in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research